<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d581" origId="Leflunomide"><sentence id="DrugDDI.d581.s0" origId="s0" text="Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration ."><entity id="DrugDDI.d581.s0.e0" origId="s0.p0" charOffset="0-14" type="drug" text="Cholestyramine"/><entity id="DrugDDI.d581.s0.e1" origId="s0.p2" charOffset="19-27" type="drug" text="Charcoal"/><entity id="DrugDDI.d581.s0.e2" origId="s0.p3" charOffset="46-60" type="drug" text="cholestyramine"/><entity id="DrugDDI.d581.s0.e3" origId="s0.p5" charOffset="64-82" type="drug" text="activated charcoal"/><entity id="DrugDDI.d581.s0.e4" origId="s0.p21" charOffset="187-204" type="drug" text="active metabolite"/><entity id="DrugDDI.d581.s0.e5" origId="s0.p22" charOffset="208-219" type="drug" text="leflunomide"/><pair id="DrugDDI.d581.s0.p0" e1="DrugDDI.d581.s0.e0" e2="DrugDDI.d581.s0.e1" interaction="?"/><pair id="DrugDDI.d581.s0.p1" e1="DrugDDI.d581.s0.e0" e2="DrugDDI.d581.s0.e2" interaction="?"/><pair id="DrugDDI.d581.s0.p2" e1="DrugDDI.d581.s0.e0" e2="DrugDDI.d581.s0.e3" interaction="?"/><pair id="DrugDDI.d581.s0.p3" e1="DrugDDI.d581.s0.e0" e2="DrugDDI.d581.s0.e4" interaction="?"/><pair id="DrugDDI.d581.s0.p4" e1="DrugDDI.d581.s0.e0" e2="DrugDDI.d581.s0.e5" interaction="?"/><pair id="DrugDDI.d581.s0.p5" e1="DrugDDI.d581.s0.e1" e2="DrugDDI.d581.s0.e2" interaction="?"/><pair id="DrugDDI.d581.s0.p6" e1="DrugDDI.d581.s0.e1" e2="DrugDDI.d581.s0.e3" interaction="?"/><pair id="DrugDDI.d581.s0.p7" e1="DrugDDI.d581.s0.e1" e2="DrugDDI.d581.s0.e4" interaction="?"/><pair id="DrugDDI.d581.s0.p8" e1="DrugDDI.d581.s0.e1" e2="DrugDDI.d581.s0.e5" interaction="?"/><pair id="DrugDDI.d581.s0.p9" e1="DrugDDI.d581.s0.e2" e2="DrugDDI.d581.s0.e3" interaction="?"/><pair id="DrugDDI.d581.s0.p10" e1="DrugDDI.d581.s0.e2" e2="DrugDDI.d581.s0.e4" interaction="?"/><pair id="DrugDDI.d581.s0.p11" e1="DrugDDI.d581.s0.e2" e2="DrugDDI.d581.s0.e5" interaction="?"/><pair id="DrugDDI.d581.s0.p12" e1="DrugDDI.d581.s0.e3" e2="DrugDDI.d581.s0.e4" interaction="?"/><pair id="DrugDDI.d581.s0.p13" e1="DrugDDI.d581.s0.e3" e2="DrugDDI.d581.s0.e5" interaction="?"/><pair id="DrugDDI.d581.s0.p14" e1="DrugDDI.d581.s0.e4" e2="DrugDDI.d581.s0.e5" interaction="?"/></sentence><sentence id="DrugDDI.d581.s1" origId="s1" text="Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances."><entity id="DrugDDI.d581.s1.e0" origId="s1.p25" charOffset="12-17" type="drug" text="Drugs"/><entity id="DrugDDI.d581.s1.e1" origId="s1.p31" charOffset="56-67" type="drug" text="leflunomide"/><pair id="DrugDDI.d581.s1.p0" e1="DrugDDI.d581.s1.e0" e2="DrugDDI.d581.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d581.s2" origId="s2" text="This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure."><entity id="DrugDDI.d581.s2.e0" origId="s2.p42" charOffset="35-46" type="drug" text="leflunomide"/><entity id="DrugDDI.d581.s2.e1" origId="s2.p45" charOffset="77-82" type="drug" text="drugs"/><pair id="DrugDDI.d581.s2.p0" e1="DrugDDI.d581.s2.e0" e2="DrugDDI.d581.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d581.s3" origId="s3" text="In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients."><entity id="DrugDDI.d581.s3.e0" origId="s3.p52" charOffset="39-44" type="drug" text="ARAVA"/><entity id="DrugDDI.d581.s3.e1" origId="s3.p53" charOffset="50-62" type="drug" text="methotrexate"/><entity id="DrugDDI.d581.s3.e2" origId="s3.p56" charOffset="92-105" type="drug" text="liver enzymes"/><pair id="DrugDDI.d581.s3.p0" e1="DrugDDI.d581.s3.e0" e2="DrugDDI.d581.s3.e1" interaction="?"/><pair id="DrugDDI.d581.s3.p1" e1="DrugDDI.d581.s3.e0" e2="DrugDDI.d581.s3.e2" interaction="?"/><pair id="DrugDDI.d581.s3.p2" e1="DrugDDI.d581.s3.e1" e2="DrugDDI.d581.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d581.s4" origId="s4" text="All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide."><entity id="DrugDDI.d581.s4.e0" origId="s4.p68" charOffset="53-58" type="drug" text="drugs"/><entity id="DrugDDI.d581.s4.e1" origId="s4.p72" charOffset="90-101" type="drug" text="leflunomide"/><pair id="DrugDDI.d581.s4.p0" e1="DrugDDI.d581.s4.e0" e2="DrugDDI.d581.s4.e1" interaction="?"/></sentence><sentence id="DrugDDI.d581.s5" origId="s5" text="A  3-fold increase was seen in another 5 patients."/><sentence id="DrugDDI.d581.s6" origId="s6" text="All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide."><entity id="DrugDDI.d581.s6.e0" origId="s6.p85" charOffset="56-61" type="drug" text="drugs"/><entity id="DrugDDI.d581.s6.e1" origId="s6.p89" charOffset="93-104" type="drug" text="leflunomide"/><pair id="DrugDDI.d581.s6.p0" e1="DrugDDI.d581.s6.e0" e2="DrugDDI.d581.s6.e1" interaction="?"/></sentence><sentence id="DrugDDI.d581.s7" origId="s7" text="Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa)."><entity id="DrugDDI.d581.s7.e0" origId="s7.p91" charOffset="15-18" type="drug" text="met"/></sentence><sentence id="DrugDDI.d581.s8" origId="s8" text="No pharmacokinetic interaction was identified."/><sentence id="DrugDDI.d581.s9" origId="s9" text="NSAIDs In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range."><entity id="DrugDDI.d581.s9.e0" origId="s9.p105" charOffset="0-6" type="drug" text="NSAIDs"/><entity id="DrugDDI.d581.s9.e1" origId="s9.p116" charOffset="106-116" type="drug" text="diclofenac"/><entity id="DrugDDI.d581.s9.e2" origId="s9.p118" charOffset="121-130" type="drug" text="ibuprofen"/><pair id="DrugDDI.d581.s9.p0" e1="DrugDDI.d581.s9.e0" e2="DrugDDI.d581.s9.e1" interaction="?"/><pair id="DrugDDI.d581.s9.p1" e1="DrugDDI.d581.s9.e0" e2="DrugDDI.d581.s9.e2" interaction="?"/><pair id="DrugDDI.d581.s9.p2" e1="DrugDDI.d581.s9.e1" e2="DrugDDI.d581.s9.e2" interaction="?"/></sentence><sentence id="DrugDDI.d581.s10" origId="s10" text="The clinical significance of this finding is unknown;"/><sentence id="DrugDDI.d581.s11" origId="s11" text="however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed."><entity id="DrugDDI.d581.s11.e0" origId="s11.p130" charOffset="48-54" type="drug" text="NSAIDs"/></sentence><sentence id="DrugDDI.d581.s12" origId="s12" text="Tolbutamide In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range."><entity id="DrugDDI.d581.s12.e0" origId="s12.p136" charOffset="0-11" type="drug" text="Tolbutamide"/><entity id="DrugDDI.d581.s12.e1" origId="s12.p147" charOffset="111-122" type="drug" text="tolbutamide"/><pair id="DrugDDI.d581.s12.p0" e1="DrugDDI.d581.s12.e0" e2="DrugDDI.d581.s12.e1" interaction="?"/></sentence><sentence id="DrugDDI.d581.s13" origId="s13" text="The clinical significance of this finding is unknown."/><sentence id="DrugDDI.d581.s14" origId="s14" text="Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone."><entity id="DrugDDI.d581.s14.e0" origId="s14.p154" charOffset="0-8" type="drug" text="Rifampin"/><entity id="DrugDDI.d581.s14.e1" origId="s14.p158" charOffset="66-71" type="drug" text="ARAVA"/><entity id="DrugDDI.d581.s14.e2" origId="s14.p162" charOffset="112-120" type="drug" text="rifampin"/><entity id="DrugDDI.d581.s14.e3" origId="s14.p172" charOffset="180-185" type="drug" text="ARAVA"/><pair id="DrugDDI.d581.s14.p0" e1="DrugDDI.d581.s14.e0" e2="DrugDDI.d581.s14.e1" interaction="?"/><pair id="DrugDDI.d581.s14.p1" e1="DrugDDI.d581.s14.e0" e2="DrugDDI.d581.s14.e2" interaction="?"/><pair id="DrugDDI.d581.s14.p2" e1="DrugDDI.d581.s14.e0" e2="DrugDDI.d581.s14.e3" interaction="?"/><pair id="DrugDDI.d581.s14.p3" e1="DrugDDI.d581.s14.e1" e2="DrugDDI.d581.s14.e2" interaction="?"/><pair id="DrugDDI.d581.s14.p4" e1="DrugDDI.d581.s14.e1" e2="DrugDDI.d581.s14.e3" interaction="?"/><pair id="DrugDDI.d581.s14.p5" e1="DrugDDI.d581.s14.e2" e2="DrugDDI.d581.s14.e3" interaction="?"/></sentence><sentence id="DrugDDI.d581.s15" origId="s15" text="Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin."><entity id="DrugDDI.d581.s15.e0" origId="s15.p177" charOffset="29-34" type="drug" text="ARAVA"/><entity id="DrugDDI.d581.s15.e1" origId="s15.p192" charOffset="148-153" type="drug" text="ARAVA"/><entity id="DrugDDI.d581.s15.e2" origId="s15.p194" charOffset="158-166" type="drug" text="rifampin"/><pair id="DrugDDI.d581.s15.p0" e1="DrugDDI.d581.s15.e0" e2="DrugDDI.d581.s15.e1" interaction="?"/><pair id="DrugDDI.d581.s15.p1" e1="DrugDDI.d581.s15.e0" e2="DrugDDI.d581.s15.e2" interaction="?"/><pair id="DrugDDI.d581.s15.p2" e1="DrugDDI.d581.s15.e1" e2="DrugDDI.d581.s15.e2" interaction="?"/></sentence><sentence id="DrugDDI.d581.s16" origId="s16" text="Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported."><entity id="DrugDDI.d581.s16.e0" origId="s16.p195" charOffset="0-8" type="drug" text="Warfarin"/><entity id="DrugDDI.d581.s16.e1" origId="s16.p202" charOffset="61-66" type="drug" text="ARAVA"/><entity id="DrugDDI.d581.s16.e2" origId="s16.p204" charOffset="71-79" type="drug" text="warfarin"/><pair id="DrugDDI.d581.s16.p0" e1="DrugDDI.d581.s16.e0" e2="DrugDDI.d581.s16.e1" interaction="?"/><pair id="DrugDDI.d581.s16.p1" e1="DrugDDI.d581.s16.e0" e2="DrugDDI.d581.s16.e2" interaction="?"/><pair id="DrugDDI.d581.s16.p2" e1="DrugDDI.d581.s16.e1" e2="DrugDDI.d581.s16.e2" interaction="?"/></sentence></document>